title: [Obesity and cancer].
abstract: The incidence of obesity in the western world has increased dramatically during recent decades. Epidemiological data suggest that obesity is associated with an increased risk of several but not all types of cancers, with clear sex-specific differences. The underlying mechanisms are still a matter of debate. This review focuses on the potential factors linking obesity to cancer. Current experimental evidence suggests that insulin resistance and a chronic, subclinical inflammation in the visceral fat are the major metabolic events causing alterations in the levels of insulin, glucose, free fatty acids, insulin-like growth factor 1 (IGF-1) and 2, adipose tissue-derived proinflammatory cytokines and other bioactive molecules, such as adipokines (e.g. leptin and adiponectin), vascular endothelial growth factor (VEGF), sex hormones, gut microbiota and secondary bile acids. All these factors may act directly or indirectly on the tumor microenvironment to drive tumor progression via stimulation of cell survival/antiapoptosis, cell proliferation, angiogenesis and invasion/metastasis of the cancer cells. Therapeutic strategies that target dysfunctional or inflamed fat and have been shown to benefit patients include bariatric surgery, while other cell or hormone-directed interventions, such as conversion of visceral fat macrophages to an anti-inflammatory M2 phenotype or the pharmacological modulation of serum adipokine levels are still theoretical and need to be clinically evaluated for their ability to successfully treat or prevent obesity-related cancers.
authors: Abteilung Hämatologie/Onkologie, Medizinische Klinik I -ZK,UKSH Campus Lübeck, Universitätsklinikum Schleswig-Holstein, Ratzeburger Allee 160, 23538, Lübeck, Deutschland, hendrik.ungefroren@uksh.de.
authors: H
authors: H
authors: Ungefroren
authors: F
authors: F
authors: Gieseler
authors: H
authors: H
authors: Lehnert
mesh_terms: D015984:Causality; D015897:Comorbidity; D016207:Cytokines / Q000276:immunology*; D006801:Humans; D018448:Models, Immunological; D009369:Neoplasms / Q000453:epidemiology* / Q000276:immunology*; D009765:Obesity / Q000453:epidemiology* / Q000276:immunology*; D012307:Risk Factors; D059016:Tumor Microenvironment / Q000276:immunology*
chemical_list: D016207:Cytokines
references: Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):921-9
references: 18398032
references: BMC Cancer. 2010 Aug 19;10:442
references: 20723213
references: Diabetes. 2011 Feb;60(2):464-76
references: 21270259
references: Am J Public Health Nations Health. 1952 Sep;42(9):1116-20
references: 12976585
references: Invest New Drugs. 2012 Apr;30(2):758-64
references: 21057973
references: Oncol Res. 2013;21(3):165-71
references: 24512731
references: Curr Drug Discov Technol. 2011 Jun;8(2):119-25
references: 21513489
references: Gastroenterology. 2011 Jun;140(7):2000-8, 2008.e1-2
references: 21334339
references: Cell Metab. 2011 Jul 6;14 (1):67-79
references: 21723505
references: Cancer Lett. 2011 Oct 28;309(2):119-27
references: 21741763
references: Expert Rev Gastroenterol Hepatol. 2008 Oct;2(5):617-9
references: 19072337
references: Biochim Biophys Acta. 2012 Apr;1822(4):527-36
references: 22198319
references: Mol Cancer Ther. 2014 Mar;13(3):585-95
references: 24362464
references: Lancet. 2014 Aug 30;384(9945):755-65
references: 25129328
references: JAMA. 2004 Mar 10;291(10):1238-45
references: 15010446
references: Ann Oncol. 2005 Aug;16(8):1253-67
references: 15870086
references: Nature. 2013 Jul 4;499(7456):97-101
references: 23803760
references: Breast Cancer Res. 2003;5(5):239-47
references: 12927032
references: FASEB J. 2013 Dec;27(12):4757-67
references: 23964081
references: World J Gastroenterol. 2014 May 14;20(18):5177-90
references: 24833848
references: Nat Rev Cancer. 2008 Dec;8(12):915-28
references: 19029956
references: ISRN Prev Med. 2013 Apr 04;2013:680536
references: 24977095
references: J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):415-22
references: 19030971
references: Nat Med. 2011 Oct 23;17(11):1490-7
references: 22019885
references: J Clin Oncol. 2012 May 1;30(13):1553-61
references: 22473167
references: Gut Microbes. 2012 Jul-Aug;3(4):279-88
references: 22572877
references: Gut. 2011 Oct;60(10):1363-71
references: 21406387
references: Gut. 2013 Apr;62(4):561-70
references: 22735569
references: Cancer Sci. 2010 May;101(5):1073-9
references: 20345478
references: Diabetes Obes Metab. 2011 Dec;13(12):1063-72
references: 21733057
references: Gut. 2010 Mar;59(3):341-7
references: 19837679
references: Int J Cancer. 2014 Aug 15;135(4):843-61
references: 24458546
references: J Obes. 2013;2013:291546
references: 24073332
references: Int J Cancer. 2004 Mar;109(1):149-52
references: 14735482
references: Cancer Res. 2010 Jan 1;70(1):4-7
references: 20028864
references: Nutr Rev. 2009 Sep;67(9):509-26
references: 19703259
references: Gut. 2008 Nov;57(11):1531-8
references: 18676419
references: Int J Cancer. 2010 Feb 1;126(3):692-702
references: 19645011
references: Carcinogenesis. 2007 Feb;28(2):455-64
references: 16891627